De Santis, P.; Sanna, V.; Perrone, M.; Guarini, C.; Santoro, A.N.; Laface, C.; Carrozzo, D.; Oliva, G.R.; Fancellu, A.; Fedele, P.
Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading? J. Clin. Med. 2023, 12, 7325.
https://doi.org/10.3390/jcm12237325
AMA Style
De Santis P, Sanna V, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, Oliva GR, Fancellu A, Fedele P.
Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading? Journal of Clinical Medicine. 2023; 12(23):7325.
https://doi.org/10.3390/jcm12237325
Chicago/Turabian Style
De Santis, Pierluigi, Valeria Sanna, Martina Perrone, Chiara Guarini, Anna Natalizia Santoro, Carmelo Laface, Daniela Carrozzo, Gaia Rachele Oliva, Alessandro Fancellu, and Palma Fedele.
2023. "Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?" Journal of Clinical Medicine 12, no. 23: 7325.
https://doi.org/10.3390/jcm12237325
APA Style
De Santis, P., Sanna, V., Perrone, M., Guarini, C., Santoro, A. N., Laface, C., Carrozzo, D., Oliva, G. R., Fancellu, A., & Fedele, P.
(2023). Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading? Journal of Clinical Medicine, 12(23), 7325.
https://doi.org/10.3390/jcm12237325
